Pharm Exec was proud to partner this year with CBI on the eighth annual Forum on Patient Compliance, Adherence & Persistency. One of the highlights of the event is the presentation of the Strategic Patient Adherence Awards, which honor pharma-based programs to improve compliance.
The winners this year:
For best branded program AstraZeneca Canada for a program in support of Arimidex (anastrozole), an adjuvant therapy for breast cancer. The program recruits patients through pharmacies (with the help of the e-health organization Rx Canada) and provides them with a series of timed newsletters throughout the five-year course of therapy.
For best integrated program Talecris Biotherapeutics for its health management program for patients with Alpha-1 Antitrypsin Deficiency, an extremely rare hereditary condition leading to chronic obstructive pulmonary disease. Â The program is noteworthy both for its remarkable success rate and for its use of a not-for-profit patient support group to provide extensive peer counseling.
Best Disease State Adherence Program Novartis for “BP Success Zone” an education and adherence program for patients with high blood pressure. Patients enroll for a 12-month series of e-mails and mailings timed to known drop-off curves. The program focuses on knowing and reaching blood pressure goals; it offers patients blood pressure meters and has a feedback loop for healthcare providers.
Scientific Pursuit of Excellence in Adherence R&D Merck, for “The Adherence Estimator,” an elegantly researched tool for predicting which patients will display poor compliance by focusing on just three core issues: commitment to treatment, concerns over therapy, and cost.
We’ll have lots more on the individual programs and the people behind them in the June issue of Pharmaceutical Executive.